---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279818979.md"
description: "Novo Nordisk: Wegovy HD (Semaglutide 7.2 mg) has been approved in the United States. The drug has been shown to achieve a weight loss of 20.7%"
datetime: "2026-03-19T15:44:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279818979.md)
  - [en](https://longbridge.com/en/news/279818979.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279818979.md)
---

# 

Novo Nordisk: Wegovy HD (Semaglutide 7.2 mg) has been approved in the United States. The drug has been shown to achieve a weight loss of 20.7%

### Related Stocks

- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [600110.CN](https://longbridge.com/en/quote/600110.CN.md)

## Related News & Research

- [Key facts: Novo Nordisk early −21.6% 64w; Rexall delivery Canada](https://longbridge.com/en/news/286343869.md)
- [Novo Nordisk Highlights New Wegovy Pill Data](https://longbridge.com/en/news/286293294.md)
- [Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial](https://longbridge.com/en/news/286239982.md)
- [Wegovy Liver Data Broadens Semaglutide Story For Novo Nordisk Investors](https://longbridge.com/en/news/286980981.md)
- [Novo Nordisk Presents New Wegovy Data Showing Strong Weight Loss, Fat Reduction](https://longbridge.com/en/news/286138025.md)